



PNEUMOLOGIA 2016

Milano, 16 – 18 giugno 2016

Le interfacce: sappiamo già tutto?

Lara Pisani

Terapia Intensiva Respiratoria e Pneumologia
Policlinico S.Orsola-Malpighi Bologna




The interface: crucial for successful noninvasive ventilation

Eur Respir J 2004; 23: 7–8

M.W. Elliott

Reasons of NIV failure





LACK OF INTERFACES TOLERANCE

Enzo Squadrone
Pamela Frigerio
Claudio Fogliati
Cesare Gregoretti
Giorgio Conti
Massimo Antonelli
Roberta Costa
Paola Baiardi
Paolo Navalesi

**Noninvasive vs invasive ventilation
in COPD patients with severe acute
respiratory failure deemed
to require ventilatory assistance**

HEMODYNAMIC INSTABILITY
NEUROLOGICAL IMPAIRMENT
WORSENING OF ABG






State of the Art


Noninvasive Ventilation

SANGEETA MEHTA and NICHOLAS S. HILL



A European survey of noninvasive ventilation practices


C. Crimi*, A. Noto#, P. Princi†, A. Esquinas+ and S. Nava§



Eur Respir J 2010; 36: 362–369

A European survey of noninvasive ventilation practices

C. Crimi*, A. Noto#, P. Princi†, A. Esquinas+ and S. Nava§



Eur Respir J 2010; 36: 362–369

Which interface?



Non-invasive ventilation in acute respiratory failure

Stefano Nava, Nicholas Hill



Mouthpieces—placed between lips and held in place by lip seal

Advantages

- Can be applied as rotating strategy with other interfaces

Disadvantages


- Vomiting and salivation
- Possible air leaks
- Gastric distension
- Speaking difficult

Lancet 2009; 374: 250-59

ALMA MATER STUDIORUM - UNIVERSITÀ DI BOLOGNA

IL PRESENTE MATERIALE È RISERVATO AL PERSONALE DELL'UNIVERSITÀ DI BOLOGNA E NON PUÒ ESSERE UTILIZZATO AI TERMINI DI LEGGE DA ALTRE PERSONE O PER FINI NON ISTITUZIONALI

NASAL PILLOWS




NASAL PILLOWS




ADVANTAGES

- As rotating strategy
- No nasal bridge contact




DISADVANTAGES

- Monitoring Tidal Volume
- Difficult to apply when high pressures needed
- Nasal irritation




NASAL MASKS

STANDARD



EXTERNAL



ADVANTAGES


Allows expectoration

↓ risk of vomiting
↓ risk of suffocation




DISADVANTAGES

Nasal integrity
Mouth leaks
Nasal skin lesion




Oro-nasal masks




ADVANTAGES

- Reduced airleaks
- Less patient's collaboration needed




DISADVANTAGES

- Vomiting/ claustrophobia
- Cutaneous bruise
- Difficult cough
- Difficult speeching



“Total face”



Total face mask—covers mouth, nose, and eyes

Advantages


- Minimum airleaks
- Little cooperation required
- Easy fitting and application

Disadvantages

- Vomiting (risk of aspiration)
- Claustrophobia
- Speaking difficult

Lancet 2009; 374: 250-59





Helmet

**Helmet—covers the whole head and all or part of the neck
(no contact with face)**

Advantages


- Minimum airleaks
- Little cooperation required
- Absence of nasal or facial skin damage

Disadvantages

- Rebreathing
- Vomiting
- Noisy
- Asynchrony with pressure support ventilation
- Discomfort of axillae (from straps)

Lancet 2009; 374: 250–59








Do they work similarly ?

Controlled trial of oronasal versus nasal mask ventilation in the treatment of acute respiratory failure

Henry Kwok, MD; James McCormack, MD; Richard Cece, RRT; Jeanne Houtchens, RN, BSN;
Nicholas S. Hill, MD




**Nasal and oro-nasal equivalent in
improving dyspnea and respiratory rate**



Evaluation of the Total Face Mask for Noninvasive Ventilation to Treat Acute Respiratory Failure

Aylin Ozsancak, MD; Samy S. Sidhom, MD, MPH; Timothy N. Liesching, MD, FCCP;
William Howard, RRT; and Nicholas S. Hill, MD, FCCP




Total face and oro-nasal equivalent in improving dyspnea and respiratory rate

CHEST 2011; 139(5):1034-1041


Cephalic versus oronasal mask for noninvasive ventilation in acute hypercapnic respiratory failure

Intensive Care Med (2009) 35:519–526

A



Cephalic mask (n)
Facial mask (n)



Cephalic mask (n)
Facial mask (n)




Cephalic mask
Facial mask

Adaptation score



Cephalic mask
Facial mask

p=0.0328 p=0.029E






C mask (n)
F mask (n)

In conclusion, the cephalic mask has the same clinical efficacy as the oronasal mask during AHRF. In spite of a larger inner volume, the cephalic interface does not require modification of ventilatory settings and may be a satisfactory alternative to oronasal masks.




Physiological effects of different interfaces during noninvasive ventilation for acute respiratory failure*



Crit Care Med 2009 Vol. 37, No. 3




for acute respiratory failure. These findings have important clinical implications because they suggest that **interfaces may be largely interchangeable**, provided ad-



The effective dead space is not only related to the internal gas volume




Fodil R. Intensive Care Med 2011; 37: 257-62



HELMET

- Ci permette di trattare il paziente indipendentemente dal contorno facciale, anche per un periodo prolungato di tempo.
- Sono dotati di una valvola anti soffocamento
- Esiste un ingresso che permette di effettuare un igiene di minima del paziente e degli ingressi per far passare il SNG o una cannuccia per bere






HELMET

3
Major issues



- Noise
- CO₂ rebreathing
- Asynchronies



NOISE




Inside the helmet noise exceeded 100 dB (during NIV with nasal or facial masks the noise did not exceed 70 dB)
Noise intensity is poorly affected by pressure support level and unaffected by the presence of HME filters.

Cavaliere F et al. *Intensive Care Med.* 2004;30(9):1755-60

During PSV with the helmet, the tympanometry showed a slight increase in acoustic compliance but returned to basal values after one hour, while it did not show a change with the face mask

Cavaliere F et al. *Acta Anaesthesiol Scand.* 2008;52(1):52-6.



CO₂ Rebreathing



Noninvasive Positive Pressure Ventilation Using a Helmet in Patients with Acute Exacerbation of Chronic Obstructive Pulmonary Disease

Antonelli M Anesthesiology 2004; 100:16-24

A Feasibility Study

Table 4. Complications

| Complications | Helmet (n = 33) | Mask (n = 33) | P |
|-----------------------------|--------------------|------------------|--------|
| Severe, No. (%) | | | |
| VAP | 5 (25) | 4 (12) | 0.50 |
| Septic shock, severe sepsis | 2 (6) | 4 (12) | 0.33 |
| Acute renal failure | 1 (3) | 4 (12) | 0.17 |
| Sinusitis | 0 (0) | 2 (6) | 0.24 |
| Related to NPPV, No. (%) | | | |
| Skin breakdown | 0 (0) | 4 (12) | 0.06 |
| Conjunctivitis | 0 (0) | 2 (6) | 0.24 |
| Gastric distension | 0 (0) | 0 (0) | 0.99 |
| Intolerance | 0 (0) | 6 (18) | 0.02 |
| DVT* | 1 (3) | 0 (0) | 0.51 |
| Total | 0 (0) | 12 (36) | <0.001 |



Noninvasive Positive Pressure Ventilation Using a Helmet in Patients with Acute Exacerbation of Chronic Obstructive Pulmonary Disease

A Feasibility Study

After 1 h of treatment

Paco₂ (mmHg), m (SD)
Pao₂:FiO₂, m (SD)
pH, m (SD)
Respiratory rate (breaths/min), m (SD)
Body temperature (C°), m (SD)
Systolic blood pressure (mmHg), m (SD)
Heart rate (bpm), m (SD)

At end of treatment†

Paco₂ (mmHg), m (SD)
Pao₂:FiO₂, m (SD)
pH, m (SD)
Respiratory rate (breaths/min), m (SD)
Body temperature (C°), m (SD)
Systolic blood pressure (mmHg), m (SD)
Heart rate (bpm), m (SD)

| | Helmet (n = 33) | Mask (n = 33) | P |
|---|-----------------|---------------|--------|
| Paco ₂ (mmHg), m (SD) | 75 (15) | 66 (15) | 0.01 |
| Pao ₂ :FiO ₂ , m (SD) | 193 (43) | 204 (64) | 0.30 |
| pH, m (SD) | 7.32 (0.07) | 7.34 (0.06) | 0.12 |
| Respiratory rate (breaths/min), m (SD) | 29 (6) | 28 (3) | 0.72 |
| Body temperature (C°), m (SD) | ND | ND | — |
| Systolic blood pressure (mmHg), m (SD) | 127 (23) | 131 (23) | 0.26 |
| Heart rate (bpm), m (SD) | 109 (18) | 91 (13) | <0.001 |
| Paco ₂ (mmHg), m (SD) | 68 (18) | 57 (9) | 0.002 |
| Pao ₂ :FiO ₂ , m (SD) | 211 (56) | 204 (37) | 0.60 |
| pH, m (SD) | 7.35 (0.09) | 7.39 (0.05) | 0.02 |
| Respiratory rate (breaths/min), m (SD) | 27 (9) | 26 (4) | 0.62 |
| Body temperature (C°), m (SD) | 36.9 (0.6) | 37 (0.6) | 0.90 |
| Systolic blood pressure (mmHg), m (SD) | 142 (20) | 130 (21) | 0.01 |
| Heart rate (bpm), m (SD) | 102 (22) | 86 (11) | 0.001 |


Conclusions: Helmet NPPV is feasible and can be used to treat chronic obstructive pulmonary disease patients with acute exacerbation, but it does not improve carbon dioxide elimination as efficiently as does FM NPPV.





Continuous positive airway pressure delivered with a “helmet”: Effects on carbon dioxide rebreathing*

Paolo Taccone, MD; Dean Hess, PhD, RRT; Pietro Caironi, MD; Luca M. Bigatello, MD

Necessita di gas ad alti flussi (>30L/min) per wash-out della CO₂



Crit Care Med 2004 Vol. 32, No. 10





Taccone P. et al. Am J Resp Crit Care Med 167;7:A995 (2003)

ALMA MATER STUDIORUM - UNIVERSITÀ DI BOLOGNA

IL PRESENTE MATERIALE È RISERVATO AL PERSONALE DELL'UNIVERSITÀ DI BOLOGNA E NON PUÒ ESSERE UTILIZZATO AI TERMINI DI LEGGE DA ALTRE PERSONE O PER FINI NON ISTITUZIONALI

Healthy volunteers



Costa R (*CHEST 2005; 128:2984–2990*)




Paolo Navalesi
Roberta Costa
Piero Ceriana
Annalisa Carlucci
George Prinianakis
Massimo Antonelli
Giorgio Conti
Stefano Nava


Non-invasive ventilation in chronic obstructive pulmonary disease patients: helmet versus facial mask

Intensive Care Med (2007) 33:74–81

* = p<0.05 vs. spontaneous breathing



PS 12; PEEP 5








Paolo Navalesi
Roberta Costa
Piero Ceriana
Annalisa Carlucci
George Prinianakis
Massimo Antonelli
Giorgio Conti
Stefano Nava

Non-invasive ventilation in chronic obstructive pulmonary disease patients: helmet versus facial mask

Intensive Care Med (2007) 33:74–81






How to overcome the problem of asynchrony and CO₂ rebreathing?

Helmet with specific settings versus facemask for noninvasive ventilation*

Frédéric Vargas, MD; Arnaud Thille, MD; Aissam Lyazidi, Biomed Eng Master; Ferran Roche Campo, MD; Laurent Brochard, MD, PhD




Hsame= Helmet with same setting of the mask

Hspec= PEEP and PS increased of 50%

| | SB Initial | FM | Hsame | Hspec |
|--|---------------------|-------------------------------|--------------------------------|-------------------------------|
| Pdi (cm H ₂ O) | 6.6 (5.1–10.3) | 3.0 (1.8–4.9) ^a | 4.9 (2.4–5.2) ^b | 2.5 (1.5–3.7) ^a |
| PTPdi/min (cm H ₂ O·s·min ⁻¹) | 209.3 (129.8–259.6) | 63.8 (27.3–85.9) ^a | 81.8 (36.0–111.5) ^b | 58.0 (25.4–79.5) ^a |


(Crit Care Med 2009; 37:1921–1928)



Helmet with specific settings versus facemask for noninvasive ventilation*

Frédéric Vargas, MD; Arnaud Thille, MD; Aissam Lyazidi, Biomed Eng Master; Ferran Roche Campo, MD; Laurent Brochard, MD, PhD

Conclusions: Our results suggest that increasing both the pressure-support level and positive end-expiratory pressure and using the highest pressurization rate may be advisable when providing NPSV via a helmet. (Crit Care Med 2009; 37:1921–1928)



NEW HELMET


ALMA MATER STUDIORUM - UNIVERSITÀ DI BOLOGNA

IL PRESENTE MATERIALE È RISERVATO AL PERSONALE DELL'UNIVERSITÀ DI BOLOGNA E NON PUÒ ESSERE UTILIZZATO AI TERMINI DI LEGGE DA ALTRE PERSONE O PER FINI NON ISTITUZIONALI

Bench comparative evaluation of a new generation and standard helmet for delivering non-invasive ventilation

Olivieri C Intensive Care Med (2013) 39:734–738

(a)




SH

(b)




NH



Castar-R Next, Intersurgical (ex-StarMed)
Italy

4. Anello apribile
2. Cuscino gonfiabile che stabilizza il casco
3. Linea per gonfiaggio cuscino



Comparative evaluation of three interfaces for non-invasive ventilation: a randomized cross-over design physiologic study on healthy volunteers

Rosanna Vaschetto^{1,2}, Audrey De Jong², Matthieu Conseil², Fabrice Galia², Martin Mahul², Yannael Coisel², Albert Prades², Paolo Navalesi^{3,4,5} and Samir Jaber^{2,6*}






Figure 1 Schematic representation of the experimental design. (A) Spontaneous breathing; (B) face mask; (C) helmet standard; (D) helmet next. Pao, pressure at the airway opening; Pes, esophageal pressure; Pga, gastric pressure.



CRITICAL CARE

| | PS 5; PEEP 5 | | PS 8; PEEP 8 | |
|-------------------------|-------------------|----------------|--------------------|----------------|
| | Baseline settings | | Increased settings | |
| | FM | H _S | H _N | H _S |
| V _T ml | 596 ± 147 | 794 ± 250 | 821 ± 240 | 882 ± 276 |
| RRn breath/minute | 15 ± 7 | 14 ± 5 | 14 ± 5 | 13 ± 4 |
| V _E L/minute | 8.1 ± 2.3 | 10.2 ± 2.7 | 11.1 ± 4.9 | 10.6 ± 3.0 |
| PTPdi/breath | 17.0 ± 11.0 | 16.6 ± 10.0 | 15.7 ± 10.7 | 13.0 ± 10.5 |
| PTPdi/minute | 204 ± 81 | 201 ± 92 | 198 ± 109 | 142 ± 80 |
| PTPdi/L | 30.2 ± 16.8 | 21.6 ± 10.5 | 20.9 ± 13.2 | 15.2 ± 10.0 |
| | | | | 12.6 ± 9.9 |

Vaschetto et al. Critical Care 2014, 18:R2



Critical Care

PS 5; PEEP 5

Delay,TR-insp (s)

FM
 0.181 ± 0.086

Delay,TR-exp (s)

FM
 0.275 ± 0.038

TI,Synchrony (%)

FM
 90 ± 4

H_S

0.354 ± 0.081

H_N

0.276 ± 0.091

≠

0.395 ± 0.093

0.301 ± 0.044

=

H_N

PS 8; PEEP 8

H_S

Delay,TR-insp (s)

0.345 ± 0.073

0.230 ± 0.061

Delay,TR-exp (s°)

0.367 ± 0.074

0.290 ± 0.099

TI,Synchrony (%)


80 ± 5

85 ± 2

Vaschetto et al. Critical Care 2014, 18:R2

ALMA MATER STUDIORUM - UNIVERSITÀ DI BOLOGNA

IL PRESENTE MATERIALE È RISERVATO AL PERSONALE DELL'UNIVERSITÀ DI BOLOGNA E NON PUÒ ESSERE UTILIZZATO AI TERMINI DI LEGGE DA ALTRE PERSONE O PER FINI NON ISTITUZIONALI




CLINICAL APPLICATION

ALMA MATER STUDIORUM - UNIVERSITÀ DI BOLOGNA

IL PRESENTE MATERIALE È RISERVATO AL PERSONALE DELL'UNIVERSITÀ DI BOLOGNA E NON PUÒ ESSERE UTILIZZATO AI TERMINI DI LEGGE DA ALTRE PERSONE O PER FINI NON ISTITUZIONALI

Oronasal mask versus helmet in acute hypercapnic respiratory failure

Lara Pisani¹, Chiara Mega¹, Rosanna Vaschetto², Andrea Bellone³, Raffaele Scala⁴, Roberto Cosentini⁵, Muriel Musti⁶, Manuela Del Forno¹, Mario Grassi⁷, Luca Fasano⁸, Paolo Navalesi^{9,10,11} and Stefano Nava¹






Eur Respir J 2015; 45: 691–699

Baseline characteristics of the patients


| | Helmet | Mask |
|--|--------------|--------------|
| Subjects n | 39 | 41 |
| Age years | 78.36±10.58 | 78.48±7.75 |
| Kelly score | 2.28±1.21 | 2.19±1.23 |
| SAPS II | 35.41±10.36 | 35.68±10.51 |
| Dyspnoea score | 7.68±2.20 | 7.06±2.75 |
| Charlson index | 3.49±1.60 | 3.49±1.88 |
| Secretions | 1.78±0.95 | 2.10±1.04 |
| Systolic blood pressure mmHg | 139.15±31.03 | 140.8±31.85 |
| Diastolic blood pressure mmHg | 73.23±17.47 | 73.38±21.26 |
| Heart rate beats per min | 98.08±17.58 | 98.02±20.27 |
| Respiratory rate breaths per min | 30.82±8.10 | 32.88±8.75 |
| Body temperature °C | 36.40±0.42 | 36.70±0.85 |
| Arterial pH | 7.27±0.05 | 7.26±0.06 |
| PaO₂ mmHg | 70.84±31.05 | 68.95±39.97 |
| PaCO₂ mmHg | 72.58±14.87 | 74.45±15.25 |
| HCO₃⁻ mmol·L⁻¹ | 30.68±6.97 | 31.32±7.24 |
| PaO₂/FiO₂ | 193.33±50.74 | 194.05±67.89 |

PRIMARY OUTCOME





| | Helmet | Mask |
|----------------------------|---------------------------|----------------------------------|
| Subjects n | 39 | 41 |
| Change of interface | 2 (5.1) | 1 (2.4) |
| Reason | Claustrophobia in 2 (5.1) | Deterioration of ABGs in 1 (2.4) |
| ETI | 0 (0) | 2 (4.8) |
| Side-effects | | |
| Noise | 4 (10.2) | 0 (0) |
| Claustrophobia | 2 (5.1) | 1 (2.4) |
| Gastric distension | 2 (5.1) | 2 (4.8) |
| Vomiting | 0 (0) | 1 (2.4) |
| Sweating | 0 (0) | 0 (0) |
| Tightness | 3 (7.6) | 5 (12.1) |



EXTENDING CLINICAL INDICATION


ALMA MATER STUDIORUM - UNIVERSITÀ DI BOLOGNA

IL PRESENTE MATERIALE È RISERVATO AL PERSONALE DELL'UNIVERSITÀ DI BOLOGNA E NON PUÒ ESSERE UTILIZZATO AI TERMINI DI LEGGE DA ALTRE PERSONE O PER FINI NON ISTITUZIONALI


New versus Conventional Helmet for Delivering Noninvasive Ventilation

A Physiologic, Crossover Randomized Study in Critically Ill Patients

Patients at risk for post-extubation failure



Anesthesiology. 2016 Jan;124(1):101-8.



SECONDARY OUTCOMES

| | ET | NH | SH |
|--|------------------|-------------------|--------------------|
| pH | 7.42 (7.40–7.46) | 7.44 (7.40–7.46) | 7.42 (7.40–7.43) |
| Paco ₂ (mmHg) | 39.5 (37.1–43.6) | 38.7 (36.1–44.7) | 40.1 (38.3–53.3) |
| Pao ₂ :FIO ₂ | 219 (184–240) | 242 (192–269) | 224(204–289) |
| Delay _{TR-insp} (s) | 0.12 (0.09–0.19) | 0.25 (0.18–0.31)* | 0.31 (0.22–0.43)†‡ |
| Delay _{TR-exp} (s) | 0.17 (0.15–0.24) | 0.10 (0.05–0.14)* | 0.13 (0.08–0.21) |
| Time _{synch} /Ti _{neu} | 0.85 (0.77–0.90) | 0.71 (0.61–0.81)* | 0.64 (0.48–0.72)†‡ |

Anesthesiology. 2016 Jan;124(1):101-8.

Effect of Noninvasive Ventilation Delivered by Helmet vs Face Mask on the Rate of Endotracheal Intubation in Patients With Acute Respiratory Distress Syndrome

A Randomized Clinical Trial

JAMA. doi:10.1001/jama.2016.6338
Published online May 15, 2016.

Bhakti K. Patel, MD; Krysta S. Wolfe, MD; Anne S. Pohlman, MSN; Jesse B. Hall, MD; John P. Kress, MD



A single-center trial of 83 patients with ARDS

AIM: To determine whether NIV delivered by helmet improves intubation rate among patients with ARDS

Eligible patients had received facemask NIV for at least 8 hours as part of their usual clinical care

Table 2. Primary and Secondary Outcomes and Adverse Events

| | Face Mask (n = 39) | Helmet (n = 44) | Absolute Difference (95% CI) | P Value |
|--|-----------------------|--------------------|------------------------------------|---------|
| Primary outcome, No. (%) | | | | |
| Endotracheal intubation | 24 (61.5) | 8 (18.2) | -43.3 (-62.4 to -24.3) | <.001 |
| Reason for intubation | | | | |
| Respiratory failure | 20 (83.3) | 3 (37.5) | -45.3 (-82.5 to -9.1) | .01 |
| Circulatory failure | 3 (12.5) | 0 (0) | -12.5 (-25.7 to 0.7) | .55 |
| Neurologic failure | 1 (4.2) | 5 (62.5) | 58.3 (24.8 to 92.8) | .001 |
| Secondary outcomes, median (IQR), d | | | | |
| Ventilator-free days | 12.5 (0.49-28) | 28 (13.7-28) | 8.4 (13.4 to 3.4) | <.001 |
| ICU length of stay | 7.8 (3.9-13.8) | 4.7 (2.5-8.7) | -2.76 (-6.07 to 0.54) | .04 |
| Hospital length of stay | 15.2 (7.8-19.7) | 10.1 (6.5-15.9) | -2.92 (-8.47 to 2.63) | .16 |
| Mortality, No. (%) | | | | |
| Hospital | 19 (48.7) | 12 (27.3) | -21.4 (-41.9 to -1.0) | .04 |
| 90 d ^a | 22 (56.4) | 15 (34.1) | -22.3 (-43.3 to -1.4) | .02 |
| Adverse events | | | | |
| Mask deflation | 0 (0) | 2 (4.5) | | |
| Skin ulceration | 3 (7.6) | 3 (6.8) | | |



No. at risk

| | | | | | | | |
|-----------|----|----|----|----|----|----|----|
| Face mask | 39 | 20 | 18 | 18 | 18 | 18 | 17 |
| Helmet | 44 | 33 | 31 | 29 | 29 | 29 | 29 |

Effect of Noninvasive Ventilation Delivered by Helmet vs Face Mask on the Rate of Endotracheal Intubation in Patients With Acute Respiratory Distress Syndrome

A Randomized Clinical Trial

JAMA. doi:10.1001/jama.2016.6338
Published online May 15, 2016.

Bhakti K. Patel, MD; Krysta S. Wolfe, MD; Anne S. Pohlman, MSN; Jesse B. Hall, MD; John P. Kress, MD

The data and safety monitoring board stopped the trial early, citing superior efficacy of helmet NIV and new data from another trial that raised concerns about the efficacy of facemask NIV in patients with AHRF (*Frat NEJM 2015;372(23):2185-2196*)

NHF vs O₂ vs NIV in hypoxemic ARF

High-Flow Oxygen through Nasal Cannula in Acute Hypoxemic Respiratory Failure

Jean-Pierre Frat, M.D., Arnaud W. Thille, M.D., Ph.D., Alain Mercat, M.D., Ph.D., Christophe Girault, M.D., Ph.D., Stéphanie Ragot, Pharm.D., Ph.D., Sébastien Perbet, M.D., Gwénael Prat, M.D., Thierry Boulain, M.D.,


310 pz

RR >25 a/min; PaO₂/FiO₂ ≤300, PaCO₂ ≤45 mmHg

No chronic respiratory diseases


O₂> 10 L/min

PEEP= 2-10 cmH₂O (5±1)
PS to reach VT 7-10 mL/kg (8±3)



For 2 days

>8hrs/day x 2 days



SpO₂ ≥92%


94
Oxygen group

106
HFNC group

110
NIV/HFNC group

Primary outcome

A Overall Population




No. at Risk

| | 106 | 68 | 67 | 67 | 65 | 65 | 65 | 65 |
|-------------------------|-----|----|----|----|----|----|----|----|
| High-flow oxygen | 106 | 68 | 67 | 67 | 65 | 65 | 65 | 65 |
| Standard oxygen | 94 | 52 | 50 | 49 | 49 | 49 | 48 | 48 |
| Noninvasive ventilation | 110 | 64 | 57 | 53 | 53 | 53 | 53 | 52 |

Primary outcome


B Patients with a $\text{PaO}_2:\text{FiO}_2 \leq 200$ mm Hg



No. at Risk

| | 0 | 4 | 8 | 12 | 16 | 20 | 24 | 28 |
|-------------------------|----|----|----|----|----|----|----|----|
| High-flow oxygen | 83 | 55 | 54 | 54 | 53 | 53 | 53 | 53 |
| Standard oxygen | 74 | 37 | 35 | 34 | 34 | 34 | 33 | 33 |
| Noninvasive ventilation | 81 | 41 | 34 | 32 | 32 | 32 | 32 | 32 |

NHF vs O₂ vs NIV in hypoxemic ARF




With NHF:

- Lower dyspnea
- Lower patient's discomfort
- Lower respiratory rate


VS O₂ and NIV group

| No. at Risk | |
|-------------|--|
| High-flow | |
| Standard | |
| Noninvas | |



Take home messages

- La NIV con il casco presenta dei problemi tecnici (re-breathing CO₂ e asincronie) che possono comprometterne il successo
- Il ventilatore sarebbe da evitare in CPAP e in NIV salvo che non vengano effettuate le dovute modifiche di setting





Take home messages

Il nuovo casco:

- ✓ Nell'ipercapnico è efficace quanto la FM nel ridurre la PaCO₂, ma sempre migliorando il setting
- ✓ Nell'ipossiemico migliora il comfort e la sincronia paziente/ventilatore rispetto al SH a parità di efficacia

Sono necessari ulteriori studi per confermare i dati nei pazienti con ARDS (NHF vs HELMET?).

Rotating strategy...



.... Prevention is BETTER!



Quino



Effect of a heated humidifier during continuous positive airway pressure delivered by a helmet

Chiumello D *Critical Care* 2008, 12:R55



Temperature and humidity of the medical gas with and without the heated humidifier in patients with acute respiratory failure





25

We don't know the long term effects with and without HH in term of Comfort and Efficacy of treatment

absolute
minimum
humidity
required for
medical
gases during
NPPV



Exhaled Air Dispersion During Noninvasive Ventilation via Helmets and a Total Facemask



Hui DS CHEST 2015; 147(5):1336-1343

